-
UCB expands executive committee
BRUSSELS — UCB announced that it will add two members to its executive committee, effective July 1.
The drug maker said that Greg Duncan, currently SVP and president of UCB’s North American operations, and Jean-Christophe Tellier, who is joining the company from Ipsen, now are the heads of the U.S. and European commercial operations, respectively.
-
Tribenzor well-tolerated among older patients in study
PARSIPPANY, N.J. — A drug made by Daiichi-Sankyo was safe and effective in maintaining reductions in blood pressure in older patients, according to a new study presented at the American Society of Hypertension’s 26th annual meeting in New York.
The “TRINITY” study of Tribenzor (olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide) showed the drug was well-tolerated and effective in patients ranging in age from younger than 65 years to older than 65 years, after a year.